Original articles

Prenatal serological screening for Down's syndrome in second trimester of pregnancy

Expand
  • Department of Clinical Laboratory, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China

Received date: 2016-11-05

  Online published: 2017-04-25

Abstract

Objective: To investigate the value of second trimester prenatal serological screening for Down's syndrome by analyzing the positive rate of serological screening and the detection rate of Down's syndrome. Methods: From January to December 2014, prenatal serological screening for Down's syndrome was performed in 19 718 pregnant women in 14-21 weeks of pregnancy. Combined detection of alpha fetoprotein (AFP), β-human chorionic gonadotropin (β-hCG) and unconjugated estriol(uE3) was performed on Beckman Access 2 Automatic Chemiluminescence Analyzer. Calculated the multiples of median (MoM) of above three indices and in coordinating with maternal age, body weight and weeks of pregnancy to predict the risk of 21-trisomy, open spine bifida (OSB), 18-Trisomy, and the pregnancy outcome was followed. Results: In the 19 718 pregnant women, serological triple screening revealed that 1 264 pregnant women were in high risk and had a positive screening rate of 6.41%. Among 18 660 pregnant women under 35 years old, 1 015 were in high risk and had a positive screening rate of 5.44%;; while for 1 058 pregnant women over 35 years old, 249 cases were in high risk and had a positive screening rate of 23.53%. Follow-up study showed that 11 pregnant women had baby with Down's syndrome, including 9 with screening positive and 2 with screening negative. The detection rate of 21-Trisomy was 82%. Follow-up also confirmed 2 cases of 18-Trisomy and 6 cases of other deformities. Conclusions: In considering the detection rate, economic aspect and operability of laboratory, serological screening in second trimester is still an important approach for screening Down′s syndrome, besides, 18-Trisomy, OSB and some other deformities can also been screened.

Cite this article

ZHANG Bin, YUE Chaoyan, YING Chunmei . Prenatal serological screening for Down's syndrome in second trimester of pregnancy[J]. Journal of Diagnostics Concepts & Practice, 2017 , 16(02) : 213 -216 . DOI: 10.16150/j.1671-2870.2017.02.018

References

[1] 吴刚, 伦玉兰. 中国优生科学[M]. 北京: 科学技术文献出版社,2000:306-307.
[2] 中华人民共和国卫生部. 中华人民共和国卫生行业标准(WS 322.1-2010)[S]. 北京: 中国标准出版社,2010.
[3] 沈凤贤, 赵丽, 吕时铭, 等. 中孕期唐氏综合征产前筛查的质量管理[J]. 中华检验医学杂志,2014,37(11):870-875.
[4] 刘春燕, 何斌, 韩代文, 等. 中孕期唐氏综合征血清学筛查在高龄孕妇中的应用价值探讨[J/OL]. 中华妇幼临床医学杂志(电子版),2016,12(2):162-163.
[5] Benn PA, Fang M, Egan JF.Trends in the use of second trimester maternal serum screening from 1991 to 2003[J]. Genet Med,2005,7(5):328-331.
[6] ACOG Committee on Practice Bulletins.ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities[J]. Obstet Gynecol,2007,109(1):217-227.
[7] Wilson KL, Czerwinski JL, Hoskovec JM, et al.NSGC practice guideline: prenatal screening and diagnostic testing options for chromosome aneuploidy[J]. J Genet Couns,2013,22(1):4-15.
[8] Hixson L, Goel S, Schuber P, et al.An Overview on prenatal screening for chromosomal aberrations[J]. J Lab Autom,2015,20(2):562-573.
[9] 韩鹏, 陈英耀, 唐智柳. 国内唐氏综合征产前筛查文献系统性综述[J]. 中国妇幼保健,2008,23(34):4939-4942.
Outlines

/